Name

PCE

Alternate names

None

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for PCE

Name

Alternate Names

Cis-Platin
Cis-Platinum II#
Cisplatino (Spanish)
Cisplatinum
Cisplatyl
Neoplatin
Peyrone's chloride
Platinex
Platinol
Platinol-AQ
Platinol-AQ VHA Plus
Platinum

Abbreviations

CACP
CDDP
Cis-DDP
CPD
CPDC
CPDD
CPPD
DDP

Category

Chemotherapy

Subcategory

Alkylating agent
Platinum analog

NSC Number

119875

Primary Site

Bladder
ovarian
testicular cancer

Histology

None

Remarks

An alkylating antineoplastic agent. FDA approved uses on bladder, ovarian and testicular cancer; miscellaneous agent.

Coding

This drug should be coded

Name

Alternate Names

Asta B 518
B-518
Clafen Claphene
Cyclophosphamid
Cyclophosphan
Cyclophosphane
Cytophosphan
Cytoxan
Endoxan
Endoxana
Enduxan
Genoxal
Neosar
Procytox
Sendoxan
Tymtram
WR-138719

Abbreviations

CP
CPM
CTX
CTY
CYC
Cyclo
CYT
CYTOX
CYTX

Category

Chemotherapy

Subcategory

Alkylating agent

NSC Number

026271
26271

Primary Site

Breast
leukemia
lymphoma
multiple myeloma
neuroblastoma
ovarian cancer
retinoblastoma
soft tissue sarcoma
Wilm's tumor

Histology

None

Remarks

An effective antineoplastic agent and is used for a variety of cancers. FDA approved uses on breast cancer, ovarian carcinoma, leukemia, lymphomas, multiple myeloma, neuroblastma, retinoblastoma, soft tissue sarcoma, Wilm's tumor. Alkylating agent

Coding

This drug should be coded

Name

Alternate Names

Compound 112531
Eldesine
Eldisine
Lilly 99094
LY-099094
Vincaleukoblastine
Vindesine sulfate

Abbreviations

DAVA
DVA

Category

Chemotherapy

Subcategory

Plant alkyloid

NSC Number

245467

Primary Site

None

Histology

None

Remarks

Vindesine has activity in a wide variety of malignancies including colorectal, lung, breast, and esophageal carcinomas; it also has activity in lymphomas and leukemias, glioma, and melanoma. Neurotoxicity (dose-limiting and cumulative) and cross-resistance with vincristine have limited the usefulness of this agent. Although vindesine in combination with cisplatin is one of the most active regimens for non-small cell lung cancer.

Coding

This drug should be coded
Glossary